The heart failure drugs market share is expected to increase by USD 2.69 billion from 2021 to 2026, and the market’s growth momentum will accelerate at a CAGR of 7.75%.
The heart failure drugs market has been broadly categorized into the following demographic segmentations:
- Drug class - Beta-blockers, ARBs, ACE inhibitors, and others
- Geography - North America, Europe, Asia, and ROW
This heart failure drugs market research report provides valuable insights on the post COVID-19 impact on the market, which will help companies evaluate their business approaches. The heart failure drugs market report offers information on several market vendors, including Amgen Inc., AstraZeneca Plc, Bayer AG, Bristol-Myers Squibb Co., Daiichi Sankyo Co. Ltd., Eli Lilly and Co., Exelixis Inc., Gilead Sciences Inc., Novartis AG, and Pfizer Inc. among others.
What will the Heart Failure Drugs Market Size be During the Forecast Period?
Download the Free Report Sample to Unlock the Heart Failure Drugs Market Size for the Forecast Period and Other Important Statistics
Heart Failure Drugs Market: Key Drivers, Trends, and Challenges
The rising geriatric population is notably driving the heart failure drugs market growth, although factors such as a highly genericized market may impede the market growth. Our research analysts have studied the historical data and deduced the key market drivers and the COVID-19 pandemic impact on the heart failure drugs industry. The holistic analysis of the drivers will help in deducing end goals and refining marketing strategies to gain a competitive edge.
Key Heart Failure Drugs Market Driver
The rising geriatric population is one of the key drivers supporting the heart failure drugs market growth. A sedentary lifestyle for several years is directly associated with the increased risk of CVDs, type 2 diabetes, and premature mortality. It has been observed in various studies that people with a sedentary lifestyle have a significantly higher rate of heart failure compared with those who lead a more active lifestyle. Moreover, there are working professionals who spend more than 50% of their day sitting without any physical movement and tend to be at a higher risk of developing CVDs such as heart failure, which will drive market growth during the forecast period.
Key Heart Failure Drugs Market Trend
Growing strategic alliances is another factor supporting the heart failure drugs market growth. As the global heart failure drugs market is highly dominated by generics, the market has the presence of many large and small players. Such fragmented nature of the market results in the distribution of profits among too many participants. As the average cost that a firm incurs toward drug development is around $2-$3 billion, such distribution provides minimal economic benefits to the market players. To overcome this situation, the market has been witnessing a growing trend of strategic alliances and acquisitions where players with strong economic positions either buy the desired drug or the entire firm. Vendors also form joint ventures for drug development or enter into a partnership, or acquire other adjacent vendors for various drugs. Such initiatives will increase the business activities of vendors, thereby driving the market growth.
Key Heart Failure Drugs Market Challenge
A highly genericized market is one of the key factors hindering the heart failure drugs market growth. The global heart failure drugs market is highly genericized, which means the generic versions of the drugs have captured a huge portion of the market. The cost-effectiveness and high affordability of these generic drugs received huge support from various government and non-government organizations, which increased the market penetration of the generic drugs further. Generic substitution (GS) successfully increased the penetration of generic drugs and reduced the overall pharmaceutical expenses of patients. However, this increased the price competition in the industry and decreased the overall revenue generated by top companies in the branded drugs market. Such factors are hindering the market growth
This heart failure drugs market analysis report also provides detailed information on other upcoming trends and challenges that will have a far-reaching effect on the market growth. The actionable insights on the trends and challenges will help companies evaluate and develop growth strategies for 2021-2025.
Parent Market Analysis
Technavio categorizes the heart failure drugs market as a part of the global pharmaceuticals market. Our research report has extensively covered external factors influencing the parent market growth potential in the coming years, which will determine the levels of growth of the heart failure drugs market during the forecast period.
Who are the Major Heart Failure Drugs Market Vendors?
The report analyzes the market’s competitive landscape and offers information on several market vendors, including:
- Amgen Inc.
- AstraZeneca Plc
- Bayer AG
- Bristol-Myers Squibb Co.
- Daiichi Sankyo Co. Ltd.
- Eli Lilly and Co.
- Exelixis Inc.
- Gilead Sciences Inc.
- Novartis AG
- Pfizer Inc.
This statistical study of the heart failure drugs market encompasses successful business strategies deployed by the key vendors. The heart failure drugs market is fragmented and the vendors are deploying growth strategies such as operational cost, innovation, price, and product quality to compete in the market.
Product Insights and News
- Amgen Inc. - The company offers heart failure drugs namely Omecamtiv Mecarbil.
To make the most of the opportunities and recover from post COVID-19 impact, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments.
The heart failure drugs market forecast report offers in-depth insights into key vendor profiles. The profiles include information on the production, sustainability, and prospects of the leading companies.
Heart Failure Drugs Market Value Chain Analysis
Our report provides extensive information on the value chain analysis for the heart failure drugs market, which vendors can leverage to gain a competitive advantage during the forecast period. The end-to-end understanding of the value chains is essential in profit margin optimization and evaluation of business strategies. The data available in our value chain analysis segment can help vendors drive costs and enhance customer services during the forecast period.
The value chain of the pharmaceuticals market includes the following core components:
- Research and development (R&D) and drug discovery
- Integration and product development
- Manufacturing
- Outbound logistics
- Marketing and sales
- Support services
- Innovation
The report has further elucidated on other innovative approaches being followed by manufacturers to ensure a sustainable market presence.
Which are the Key Regions for Heart Failure Drugs Market?
For more insights on the market share of various regions Request for a FREE sample now!
38% of the market’s growth will originate from North America during the forecast period. The US and Canada are the key markets for the heart failure drugs market in North America. Market growth in this region will be slower than the growth of the market in Asia and Europe.
The high incidence of CVDs will facilitate the heart failure drugs market growth in North America will facilitate the heart failure drugs market growth in North America over the forecast period. This market research report entails detailed information on the competitive intelligence, marketing gaps, and regional opportunities in store for vendors, which will assist in creating efficient business plans.
COVID Impact and Recovery Analysis
The outbreak of COVID-19 led to a slight decline in growth of the heart failure drugs market in North America in Q1 2020 owing to a temporary pause on the research of new drugs for heart failure treatment and reduced clinic visits because of the stay-at-home policy. However, the adoption of telehealth and lifting of stay-at-home policy regained the market revenue in the region. In addition, resuming normalcy and fastened research programs of heart failure drugs are expected to increase the growth of the regional market during the forecast period.
What are the Revenue-generating Drug Class Segments in the Heart Failure Drugs Market?
To gain further insights on the market contribution of various segments Request for a FREE sample
The heart failure drugs market share growth by the beta-blockers segment will be significant during the forecast period. Beta-blocker is a class of medication used to manage and treat several heart diseases, and heart failure is one among them. These drugs are competitive antagonists that block the effect of stress hormones such as adrenaline on the heart. They reduce blood pressure, heart rate and hence reduce the workload of the heart. Drugs such as Toprol-XL led to a high share of the segment in the global heart failure drugs market. This, in turn, will drive the heart failure drugs market growth during the forecast period.
This report provides an accurate prediction of the contribution of all the segments to the growth of the heart failure drugs market size and actionable market insights on post COVID-19 impact on each segment.
|
Heart Failure Drugs Market Scope |
|
|
Report Coverage |
Details |
|
Page number |
120 |
|
Base year |
2020 |
|
Forecast period |
2021-2025 |
|
Growth momentum & CAGR |
Accelerate at a CAGR of 7.75% |
|
Market growth 2021-2025 |
$ 2.69 billion |
|
Market structure |
Fragmented |
|
YoY growth (%) |
5.71 |
|
Regional analysis |
North America, Europe, Asia, and ROW |
|
Performing market contribution |
North America at 38% |
|
Key consumer countries |
US, Canada, Germany, UK, and China |
|
Competitive landscape |
Leading companies, Competitive strategies, Consumer engagement scope |
|
Key companies profiled |
Amgen Inc., AstraZeneca Plc, Bayer AG, Bristol-Myers Squibb Co., Daiichi Sankyo Co. Ltd., Eli Lilly and Co., Exelixis Inc., Gilead Sciences Inc., Novartis AG, and Pfizer Inc. |
|
Market dynamics |
Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID 19 impact and recovery analysis and future consumer dynamics, Market condition analysis for forecast period |
|
Customization purview |
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
What are the Key Data Covered in this Heart Failure Drugs Market Report?
- CAGR of the market during the forecast period 2021-2025
- Detailed information on factors that will drive heart failure drugs market growth during the next five years
- Precise estimation of the heart failure drugs market size and its contribution to the parent market
- Accurate predictions on upcoming trends and changes in consumer behavior
- The growth of the heart failure drugs industry across North America, Europe, Asia, and ROW
- A thorough analysis of the market’s competitive landscape and detailed information on vendors
- Comprehensive details of factors that will challenge the growth of heart failure drugs market vendors
We can help! Our analysts can customize this report to meet your requirements. Get in touch